BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015;2:351-355. [PMID: 26137574 DOI: 10.1016/j.ebiom.2015.02.015] [Cited by in Crossref: 137] [Cited by in F6Publishing: 113] [Article Influence: 22.8] [Reference Citation Analysis]
Number Citing Articles
1 Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK Inhibitors for Treatment of Alopecia Areata. J Invest Dermatol 2018;138:1911-6. [PMID: 30057345 DOI: 10.1016/j.jid.2018.05.027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 8.3] [Reference Citation Analysis]
2 Wang D, Beck LA. Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update. Am J Clin Dermatol 2016;17:425-43. [PMID: 27371134 DOI: 10.1007/s40257-016-0205-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
3 Dainichi T, Kabashima K. Alopecia areata: What's new in epidemiology, pathogenesis, diagnosis, and therapeutic options? J Dermatol Sci 2017;86:3-12. [PMID: 27765435 DOI: 10.1016/j.jdermsci.2016.10.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
4 Vasserot AP, Geyfman M, Poloso NJ. Androgenetic alopecia: combing the hair follicle signaling pathways for new therapeutic targets and more effective treatment options. Expert Opin Ther Targets 2019;23:755-71. [PMID: 31456448 DOI: 10.1080/14728222.2019.1659779] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
5 Hirahara K, Schwartz D, Gadina M, Kanno Y, O'Shea JJ. Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr Opin Immunol 2016;43:89-97. [PMID: 27821272 DOI: 10.1016/j.coi.2016.10.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
6 Shreberk-hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. Journal of the American Academy of Dermatology 2017;76:745-753.e19. [DOI: 10.1016/j.jaad.2016.12.004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 18.5] [Reference Citation Analysis]
7 Dai Z, Chen J, Chang Y, Christiano AM. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata. JCI Insight 2021;6:142205. [PMID: 33830087 DOI: 10.1172/jci.insight.142205] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tavakolpour S. Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata. Scand J Immunol 2016;83:345-6. [DOI: 10.1111/sji.12423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
9 Jabbari A, Nguyen N, Cerise JE, Ulerio G, de Jong A, Clynes R, Christiano AM, Mackay-Wiggan J. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol 2016;25:642-3. [PMID: 27119625 DOI: 10.1111/exd.13060] [Cited by in Crossref: 54] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
10 Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev 2019;18:102390. [PMID: 31520803 DOI: 10.1016/j.autrev.2019.102390] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 40.0] [Reference Citation Analysis]
11 Santos LDN, Shapiro J. What's New in Hair Loss. Dermatol Clin 2019;37:137-41. [PMID: 30850035 DOI: 10.1016/j.det.2018.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Renert-yuval Y, Guttman-yassky E. Systemic therapies in atopic dermatitis: The pipeline. Clinics in Dermatology 2017;35:387-97. [DOI: 10.1016/j.clindermatol.2017.03.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
13 Thompson HJ, Vavra T, Jabbari A. Factors associated with insurance coverage of tofacitinib for alopecia areata: A retrospective review from an academic institution. J Am Acad Dermatol 2020;83:1509-10. [PMID: 32553634 DOI: 10.1016/j.jaad.2020.06.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Richardson CT, Hayden MS, Gilmore ES, Poligone B. Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. Am J Clin Dermatol 2018;19:119-26. [DOI: 10.1007/s40257-017-0312-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Cruz MS, Diamond A, Russell A, Jameson JM. Human αβ and γδ T Cells in Skin Immunity and Disease. Front Immunol 2018;9:1304. [PMID: 29928283 DOI: 10.3389/fimmu.2018.01304] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
16 Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;17:78. [PMID: 29282366 DOI: 10.1038/nrd.2017.267] [Cited by in Crossref: 113] [Cited by in F6Publishing: 90] [Article Influence: 37.7] [Reference Citation Analysis]
17 Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol 2018;179:1033-48. [PMID: 29791718 DOI: 10.1111/bjd.16808] [Cited by in Crossref: 53] [Cited by in F6Publishing: 33] [Article Influence: 17.7] [Reference Citation Analysis]
18 Peloquin L, Castelo-soccio L. Alopecia Areata: An Update on Treatment Options for Children. Pediatr Drugs 2017;19:411-22. [DOI: 10.1007/s40272-017-0239-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Rork JF, Rashighi M, Harris JE. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr 2016;28:463-9. [PMID: 27191524 DOI: 10.1097/MOP.0000000000000375] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
20 Hirai T, Whitley SK, Kaplan DH. Migration and Function of Memory CD8+ T Cells in Skin. J Invest Dermatol 2020;140:748-55. [PMID: 31812277 DOI: 10.1016/j.jid.2019.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Trüeb RM, Dutra H, Dias MFRG. A Comment on JAK Inhibitors for Treatment of Alopecia Areata. Int J Trichology 2018;10:193-7. [PMID: 30607037 DOI: 10.4103/ijt.ijt_62_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Journal of the American Academy of Dermatology 2017;76:29-32. [DOI: 10.1016/j.jaad.2016.09.006] [Cited by in Crossref: 83] [Cited by in F6Publishing: 63] [Article Influence: 20.8] [Reference Citation Analysis]
23 Vañó-Galván S, Camacho F. New Treatments for Hair Loss. Actas Dermosifiliogr 2017;108:221-8. [PMID: 28061966 DOI: 10.1016/j.ad.2016.11.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
24 Waśkiel‐burnat A, Kołodziejak M, Sikora M, Stochmal A, Rakowska A, Olszewska M, Rudnicka L. Therapeutic management in paediatric alopecia areata: A systematic review. J Eur Acad Dermatol Venereol 2021;35:1299-308. [DOI: 10.1111/jdv.17187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Xiao P, Zhong T, Liu Z, Ding Y, Guan W, He X, Pu Y, Jiang L, Ma Y, Zhao Q. Integrated Analysis of Methylome and Transcriptome Changes Reveals the Underlying Regulatory Signatures Driving Curly Wool Transformation in Chinese Zhongwei Goats. Front Genet 2019;10:1263. [PMID: 31969898 DOI: 10.3389/fgene.2019.01263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
26 Malik K, Guttman-yassky E. Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases. Journal of Investigative Dermatology Symposium Proceedings 2018;19:S62-4. [DOI: 10.1016/j.jisp.2017.10.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
27 Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis 2020;12:1759720X20936059. [PMID: 32655703 DOI: 10.1177/1759720X20936059] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
28 Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 2016;32:29-33. [PMID: 26994322 DOI: 10.1016/j.cbpa.2016.03.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 69] [Article Influence: 16.4] [Reference Citation Analysis]
29 Shivanna CB, Shenoy C, Priya RA. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients. Int J Trichology 2018;10:103-7. [PMID: 30034188 DOI: 10.4103/ijt.ijt_21_18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
30 Pourang A, Mesinkovska NA. New and Emerging Therapies for Alopecia Areata. Drugs 2020;80:635-46. [PMID: 32323220 DOI: 10.1007/s40265-020-01293-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
31 Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol 2021;17:835-52. [PMID: 34106037 DOI: 10.1080/1744666X.2021.1940962] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol 2017;76:736-44. [PMID: 28139263 DOI: 10.1016/j.jaad.2016.12.005] [Cited by in Crossref: 164] [Cited by in F6Publishing: 124] [Article Influence: 41.0] [Reference Citation Analysis]
33 Renert-Yuval Y, Guttman-Yassky E. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm. Adv Ther 2017;34:1594-609. [PMID: 28646393 DOI: 10.1007/s12325-017-0542-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
34 Guttman-yassky E, Nia JK, Hashim PW, Mansouri Y, Alia E, Taliercio M, Desai PN, Lebwohl MG. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata. Arch Dermatol Res 2018;310:607-14. [DOI: 10.1007/s00403-018-1853-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
35 Yan B, Freiwald T, Chauss D, Wang L, West E, Bibby J, Olson M, Kordasti S, Portilla D, Laurence A, Lionakis MS, Kemper C, Afzali B, Kazemian M. SARS-CoV2 drives JAK1/2-dependent local and systemic complement hyper-activation. Res Sq 2020:rs. [PMID: 32702726 DOI: 10.21203/rs.3.rs-33390/v1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
36 Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z, Baradaran B. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol 2020;235:5903-24. [DOI: 10.1002/jcp.29593] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
37 Broadley D, McElwee KJ. A "hair-raising" history of alopecia areata. Exp Dermatol 2020;29:208-22. [PMID: 31960494 DOI: 10.1111/exd.14073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
38 Sideris N, Vakirlis E, Tsentemeidou A, Kourouklidou A, Ioannides D, Sotiriou E. Under Development JAK Inhibitors for Dermatologic Diseases. Mediterr J Rheumatol 2020;31:137-44. [PMID: 32676572 DOI: 10.31138/mjr.31.1.137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
39 Kridin K, Renert-Yuval Y, Guttman-Yassky E, Cohen AD. Alopecia Areata Is Associated with Atopic Diathesis: Results from a Population-Based Study of 51,561 Patients. J Allergy Clin Immunol Pract 2020;8:1323-1328.e1. [PMID: 32036002 DOI: 10.1016/j.jaip.2020.01.052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
40 Richmond JM, Strassner JP, Essien KI, Harris JE. T-cell positioning by chemokines in autoimmune skin diseases. Immunol Rev 2019;289:186-204. [PMID: 30977191 DOI: 10.1111/imr.12762] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
41 Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight 2016;1:e89790. [PMID: 27699253 DOI: 10.1172/jci.insight.89790] [Cited by in Crossref: 132] [Cited by in F6Publishing: 105] [Article Influence: 26.4] [Reference Citation Analysis]
42 Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers 2017;3:17011. [PMID: 28300084 DOI: 10.1038/nrdp.2017.11] [Cited by in Crossref: 140] [Cited by in F6Publishing: 91] [Article Influence: 35.0] [Reference Citation Analysis]
43 Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, Christiano AM. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv 2015;1:e1500973. [PMID: 26601320 DOI: 10.1126/sciadv.1500973] [Cited by in Crossref: 106] [Cited by in F6Publishing: 81] [Article Influence: 17.7] [Reference Citation Analysis]
44 Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clin Rev Allergy Immunol 2021. [PMID: 34403083 DOI: 10.1007/s12016-021-08883-0] [Reference Citation Analysis]
45 Assadiasl S, Fatahi Y, Mosharmovahed B, Mohebbi B, Nicknam MH. Baricitinib: From Rheumatoid Arthritis to COVID-19. J Clin Pharmacol 2021;61:1274-85. [PMID: 33870531 DOI: 10.1002/jcph.1874] [Reference Citation Analysis]
46 Honda-Ozaki F, Terashima M, Niwa A, Saiki N, Kawasaki Y, Ito H, Hotta A, Nagahashi A, Igura K, Asaka I, Li HL, Yanagimachi M, Furukawa F, Kanazawa N, Nakahata T, Saito MK. Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress. Stem Cell Reports 2018;10:1835-50. [PMID: 29731430 DOI: 10.1016/j.stemcr.2018.04.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
47 Zheng C, Tosti A. Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors. Dermatol Clin 2021;39:407-15. [PMID: 34053594 DOI: 10.1016/j.det.2021.03.005] [Reference Citation Analysis]
48 Kuhn A, Landmann A, Wenzel J. Advances in the treatment of cutaneous lupus erythematosus. Lupus 2016;25:830-7. [PMID: 27252259 DOI: 10.1177/0961203316641771] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
49 Patel N, Strowd LC. The Future of Atopic Dermatitis Treatment. Adv Exp Med Biol 2017;1027:185-210. [PMID: 29063440 DOI: 10.1007/978-3-319-64804-0_15] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, Shapiro J. Alopecia areata. Journal of the American Academy of Dermatology 2018;78:15-24. [DOI: 10.1016/j.jaad.2017.04.1142] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 26.0] [Reference Citation Analysis]
51 Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33:850-856. [PMID: 30762909 DOI: 10.1111/jdv.15489] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 19.5] [Reference Citation Analysis]
52 Hosking A, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: A review of applications in dermatology. Journal of the American Academy of Dermatology 2018;79:535-44. [DOI: 10.1016/j.jaad.2018.04.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 13.3] [Reference Citation Analysis]
53 Iorizzo M, Tosti A. Emerging drugs for alopecia areata: JAK inhibitors. Expert Opinion on Emerging Drugs 2018;23:77-81. [DOI: 10.1080/14728214.2018.1444750] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
54 Kim BY, Kim HS. Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment. Singapore Med J 2017;58:279-80. [PMID: 28536724 DOI: 10.11622/smedj.2017039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
55 Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25-36. [PMID: 26633291 DOI: 10.1038/nrrheum.2015.167] [Cited by in Crossref: 287] [Cited by in F6Publishing: 237] [Article Influence: 47.8] [Reference Citation Analysis]
56 Glickman JW, Dubin C, Dahabreh D, Han J, Del Duca E, Estrada YD, Zhang N, Kimmel GW, Singer G, Krueger JG, Pavel AB, Guttman-Yassky E. An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. Allergy 2021. [PMID: 33721346 DOI: 10.1111/all.14814] [Reference Citation Analysis]
57 Ismail FF, Sinclair R. JAK inhibition in the treatment of alopecia areata – a promising new dawn? Expert Review of Clinical Pharmacology 2020;13:43-51. [DOI: 10.1080/17512433.2020.1702878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
58 Halacoglu J, Shea LA. Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis. J Cardiovasc Transl Res 2020;13:878-90. [PMID: 32080804 DOI: 10.1007/s12265-020-09964-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
59 Renert-yuval Y, Guttman-yassky E. A novel therapeutic paradigm for patients with extensive alopecia areata. Expert Opinion on Biological Therapy 2016;16:1005-14. [DOI: 10.1080/14712598.2016.1188076] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
60 Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, Joseph S, Chitreddy V, Gunatheesan S, Sindhu K, Sharma P, Green J, Eisman S, Yip L, Jones L, Sinclair R. Treatment of alopecia areata: An Australian expert consensus statement. Australas J Dermatol 2019;60:163-70. [DOI: 10.1111/ajd.12941] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
61 Arnold R, Vehns E, Randl H, Djabali K. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells. Int J Mol Sci 2021;22:7474. [PMID: 34299092 DOI: 10.3390/ijms22147474] [Reference Citation Analysis]
62 King B, Ko J, Forman S, Ohyama M, Mesinkovska N, Yu G, McCollam J, Gamalo M, Janes J, Edson-Heredia E, Holzwarth K, Dutronc Y. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study. J Am Acad Dermatol 2021:S0190-9622(21)01088-4. [PMID: 34090959 DOI: 10.1016/j.jaad.2021.05.050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Lee S, Lee W. Management of alopecia areata: Updates and algorithmic approach. J Dermatol 2017;44:1199-211. [DOI: 10.1111/1346-8138.13933] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
64 Fuentes-Duculan J, Gulati N, Bonifacio KM, Kunjravia N, Zheng X, Suárez-Fariñas M, Shemer A, Guttman-Yassky E, Krueger JG. Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. Exp Dermatol 2016;25:282-6. [PMID: 26661294 DOI: 10.1111/exd.12918] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
65 Ocampo-garza J, Griggs J, Tosti A. New drugs under investigation for the treatment of alopecias. Expert Opinion on Investigational Drugs 2019;28:275-84. [DOI: 10.1080/13543784.2019.1568989] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
66 Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. JAAD Case Rep 2019;5:892-4. [PMID: 31681829 DOI: 10.1016/j.jdcr.2019.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
67 Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis. J Eur Acad Dermatol Venereol 2019;34:192-201. [DOI: 10.1111/jdv.15937] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
68 Volpi S, Insalaco A, Caorsi R, Santori E, Messia V, Sacco O, Terheggen-Lagro S, Cardinale F, Scarselli A, Pastorino C, Moneta G, Cangemi G, Passarelli C, Ricci M, Girosi D, Derchi M, Bocca P, Diociaiuti A, El Hachem M, Cancrini C, Tomà P, Granata C, Ravelli A, Candotti F, Picco P, DeBenedetti F, Gattorno M. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. J Clin Immunol 2019;39:476-85. [PMID: 31144250 DOI: 10.1007/s10875-019-00645-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 16.5] [Reference Citation Analysis]
69 Picard C, Belot A. Does type-I interferon drive systemic autoimmunity? Autoimmunity Reviews 2017;16:897-902. [DOI: 10.1016/j.autrev.2017.07.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
70 He H, Guttman-yassky E. JAK Inhibitors for Atopic Dermatitis: An Update. Am J Clin Dermatol 2019;20:181-92. [DOI: 10.1007/s40257-018-0413-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 46] [Article Influence: 21.0] [Reference Citation Analysis]
71 Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16:843-862. [PMID: 29104284 DOI: 10.1038/nrd.2017.201] [Cited by in Crossref: 320] [Cited by in F6Publishing: 258] [Article Influence: 80.0] [Reference Citation Analysis]
72 Ramot Y, Marzani B, Pinto D, Sorbellini E, Rinaldi F. IL-17 inhibition: is it the long-awaited savior for alopecia areata? Arch Dermatol Res 2018;310:383-90. [DOI: 10.1007/s00403-018-1823-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
73 Dobreva A, Paus R, Cogan NG. Analysing the dynamics of a model for alopecia areata as an autoimmune disorder of hair follicle cycling. Mathematical Medicine and Biology: A Journal of the IMA 2018;35:387-407. [DOI: 10.1093/imammb/dqx009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Ramot Y, Zlotogorski A. Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient. Skin Appendage Disord 2018;4:122-4. [PMID: 29765973 DOI: 10.1159/000479722] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
75 Lee JS, Huh C, Kwon O, Yoon H, Cho S, Park H. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib. Journal of Dermatological Treatment 2018;29:819-22. [DOI: 10.1080/09546634.2018.1466024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
76 Hamed FN, McDonagh AJG, Almaghrabi S, Bakri Y, Messenger AG, Tazi-Ahnini R. Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients. Int J Environ Res Public Health 2018;15:E2882. [PMID: 30558329 DOI: 10.3390/ijerph15122882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
77 Buchbinder D, Montealegre Sanchez GA, Goldbach-Mansky R, Brunner H, Shulman AI. Rash, Fever, and Pulmonary Hypertension in a 6-Year-Old Female. Arthritis Care Res (Hoboken) 2018;70:785-90. [PMID: 29316368 DOI: 10.1002/acr.23506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol 2018;78:S53-62. [PMID: 29248518 DOI: 10.1016/j.jaad.2017.12.019] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
79 Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol 2017;76:22-8. [PMID: 27816293 DOI: 10.1016/j.jaad.2016.09.007] [Cited by in Crossref: 138] [Cited by in F6Publishing: 107] [Article Influence: 27.6] [Reference Citation Analysis]
80 Wang ECE, Dai Z, Christiano AM. Novel therapies for alopecia areata: The era of rational drug development. J Allergy Clin Immunol 2018;141:499-504. [PMID: 29155099 DOI: 10.1016/j.jaci.2017.10.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
81 Akdogan N, Ersoy-Evans S, Doğan S, Atakan N. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata. Dermatol Ther 2019;32:e13118. [PMID: 31621150 DOI: 10.1111/dth.13118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Shao S, Tsoi LC, Sarkar MK, Xing X, Xue K, Uppala R, Berthier CC, Zeng C, Patrick M, Billi AC, Fullmer J, Beamer MA, Perez-White B, Getsios S, Schuler A, Voorhees JJ, Choi S, Harms P, Kahlenberg JM, Gudjonsson JE. IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med 2019;11:eaav7561. [PMID: 31554739 DOI: 10.1126/scitranslmed.aav7561] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
83 Dillon KL. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata. Clin Cosmet Investig Dermatol 2021;14:691-714. [PMID: 34211288 DOI: 10.2147/CCID.S309215] [Reference Citation Analysis]
84 Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC, Marinkovich MP, Christiano AM, Oro AE, King BA. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 2016;1:e89776. [PMID: 27699252 DOI: 10.1172/jci.insight.89776] [Cited by in Crossref: 121] [Cited by in F6Publishing: 106] [Article Influence: 24.2] [Reference Citation Analysis]
85 Montilla AM, Gómez-García F, Gómez-Arias PJ, Gay-Mimbrera J, Hernández-Parada J, Isla-Tejera B, Ruano J. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata. Dermatol Ther (Heidelb) 2019;9:655-83. [PMID: 31606872 DOI: 10.1007/s13555-019-00329-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
86 Xu P, Shen P, Yu B, Xu X, Ge R, Cheng X, Chen Q, Bian J, Li Z, Wang J. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. Eur J Med Chem 2020;192:112155. [PMID: 32120325 DOI: 10.1016/j.ejmech.2020.112155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
87 Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther 2018;12:2323-35. [PMID: 30100707 DOI: 10.2147/DDDT.S172638] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
88 Howell MD, Kuo FI, Smith PA. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Front Immunol 2019;10:2342. [PMID: 31649667 DOI: 10.3389/fimmu.2019.02342] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 17.5] [Reference Citation Analysis]
89 Gilhar A, Schrum AG, Etzioni A, Waldmann H, Paus R. Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev 2016;15:726-35. [PMID: 26971464 DOI: 10.1016/j.autrev.2016.03.008] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 9.6] [Reference Citation Analysis]
90 Paus R, Bulfone-paus S, Bertolini M. Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management. Journal of Investigative Dermatology Symposium Proceedings 2018;19:S12-7. [DOI: 10.1016/j.jisp.2017.10.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
91 Ahn H, Lee SY, Jung WJ, Lee KH. Alopecia treatment using minimally manipulated human umbilical cord-derived mesenchymal stem cells: Three case reports and review of literature. World J Clin Cases 2021;9:3741-51. [PMID: 34046478 DOI: 10.12998/wjcc.v9.i15.3741] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017;77:521-546. [PMID: 28255960 DOI: 10.1007/s40265-017-0701-9] [Cited by in Crossref: 259] [Cited by in F6Publishing: 221] [Article Influence: 64.8] [Reference Citation Analysis]
93 Żeberkiewicz M, Rudnicka L, Malejczyk J. Immunology of alopecia areata. Cent Eur J Immunol 2020;45:325-33. [PMID: 33437185 DOI: 10.5114/ceji.2020.101264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 de Oliveira AB, Alpalhão M, Filipe P, Maia-Silva J. The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review. Dermatol Ther 2019;32:e13053. [PMID: 31381252 DOI: 10.1111/dth.13053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
95 Samadi A, Ahmad Nasrollahi S, Hashemi A, Nassiri Kashani M, Firooz A. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J Dermatolog Treat 2017;28:476-83. [PMID: 28024126 DOI: 10.1080/09546634.2016.1277179] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
96 Trüeb RM, Jolliffe VML, Régnier AF, Dutra Rezende H, Vañó-Galván S, Kopera D, Ioannides D, Gavazzoni Dias MFR, Macpherson M, Gadzhigoroeva A, Ovcharenko J, Lee WS, Murugusundram S, Kurata S, Chang M, Tanglertsampan C. Precision Medicine and the Practice of Trichiatry: Adapting the Concept. Skin Appendage Disord 2019;5:338-43. [PMID: 31799259 DOI: 10.1159/000500364] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
97 Alunno A, Padjen I, Fanouriakis A, Boumpas DT. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent. Cells 2019;8:E898. [PMID: 31443172 DOI: 10.3390/cells8080898] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 19.0] [Reference Citation Analysis]
98 Klaeschen AS, Wenzel J. Upcoming therapeutic targets in cutaneous lupus erythematous. Expert Review of Clinical Pharmacology 2016;9:567-78. [DOI: 10.1586/17512433.2016.1145543] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
99 Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, Vekaria AS, Taliercio M, Singer G, Karalekas R, Baum D, Mansouri Y, Lebwohl MG, Guttman-Yassky E. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res 2019;311:29-36. [PMID: 30417279 DOI: 10.1007/s00403-018-1876-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
100 Aymeric E, Bensignor E. A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib. Vet Dermatol 2017;28:512-e123. [DOI: 10.1111/vde.12458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
101 Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J Exp Med 2016;213:2527-38. [PMID: 27821552 DOI: 10.1084/jem.20161596] [Cited by in Crossref: 220] [Cited by in F6Publishing: 175] [Article Influence: 44.0] [Reference Citation Analysis]
102 Colavincenzo ML. Practice and Educational Gaps in Dermatology. Dermatologic Clinics 2016;34:275-9. [DOI: 10.1016/j.det.2016.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Trüeb RM, Dias MFRG. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. Clin Rev Allergy Immunol 2018;54:68-87. [PMID: 28717940 DOI: 10.1007/s12016-017-8620-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
104 Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, Smith KP, Liggett LA, Gomez EB, Galbraith MD, DeGregori J, Espinosa JM. Trisomy 21 consistently activates the interferon response. Elife 2016;5:e16220. [PMID: 27472900 DOI: 10.7554/eLife.16220] [Cited by in Crossref: 117] [Cited by in F6Publishing: 62] [Article Influence: 23.4] [Reference Citation Analysis]
105 Ryan GE, Harris JE, Richmond JM. Resident Memory T Cells in Autoimmune Skin Diseases. Front Immunol 2021;12:652191. [PMID: 34012438 DOI: 10.3389/fimmu.2021.652191] [Reference Citation Analysis]
106 Peterson DM, Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. JAAD Case Rep 2020;6:257-9. [PMID: 32258291 DOI: 10.1016/j.jdcr.2020.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
107 Chiang A, Ortenzio F, Juhasz MLW, Yu V, Mesinkovska NA. Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature. JAAD Case Rep 2018;4:733-6. [PMID: 30167448 DOI: 10.1016/j.jdcr.2018.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
108 Jabbari A, Cerise JE, Chen JC, Mackay-Wiggan J, Duvic M, Price V, Hordinsky M, Norris D, Clynes R, Christiano AM. Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine 2016;7:240-7. [PMID: 27322477 DOI: 10.1016/j.ebiom.2016.03.036] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
109 Blume-peytavi U, Bagot M, Tennstedt D, Saint Aroman M, Stockfleth E, Zlotogorski A, Mengeaud V, Schmitt A, Paul C, Lim H, Georgescu V, Dréno B, Nocera T. Dermatology today and tomorrow: from symptom control to targeted therapy. J Eur Acad Dermatol Venereol 2019;33:3-36. [DOI: 10.1111/jdv.15335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
110 Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus. Journal of Investigative Dermatology 2016;136:1281-3. [DOI: 10.1016/j.jid.2016.02.015] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
111 Yan B, Freiwald T, Chauss D, Wang L, West E, Mirabelli C, Zhang CJ, Nichols EM, Malik N, Gregory R, Bantscheff M, Ghidelli-Disse S, Kolev M, Frum T, Spence JR, Sexton JZ, Alysandratos KD, Kotton DN, Pittaluga S, Bibby J, Niyonzima N, Olson MR, Kordasti S, Portilla D, Wobus CE, Laurence A, Lionakis MS, Kemper C, Afzali B, Kazemian M. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Sci Immunol 2021;6:eabg0833. [PMID: 33827897 DOI: 10.1126/sciimmunol.abg0833] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
112 Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol 2017;312:F716-31. [PMID: 27558558 DOI: 10.1152/ajprenal.00314.2016] [Cited by in Crossref: 70] [Cited by in F6Publishing: 51] [Article Influence: 14.0] [Reference Citation Analysis]
113 Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAK-inhibitors in dermatology: current evidence and future applications. Journal of Dermatological Treatment 2019;30:648-58. [DOI: 10.1080/09546634.2018.1546043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]